Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia
- 6 September 2019
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 94 (12) , 1325-1334
Abstract
Duvelisib, a potent δ‐ and γ‐PI3K inhibitor, is a potential therapeutic for hematologic malignancies. Rituximab and bendamustine have demonstrated activity in non‐Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Combining duvelisib with either rituximab alone or rituximab and bendamustine may improve response rates and remission durability. We conducted this Phase one study in relapsed/refractory NHL and CLL patients. During expansion, each arm enrolled to disease‐specific cohorts to assess efficacy. Arm one received rituximab 375 mg/m2 IV weekly for two 4‐week cycles plus duvelisib until progression/intolerance. Arm two received rituximab 375 mg/m2 IV Day one, bendamustine 90 mg/m2 IV (NHL patients) or 70 mg/m2 IV (CLL patients) Days one‐two for six cycles, plus duvelisib until progression/intolerance. Duvelisib doses of 50 mg and 75 mg BID were tested during dose escalation. Forty‐six patients (27 NHL, 19 CLL) were treated. The adverse events of the drug combinations were consistent with single agent toxicities. The most common AEs were neutropenia (47.7%), fatigue (41.3%), and rash (41.3%). A duvelisib expansion dose of 25 mg BID was chosen based on the monotherapy phase one study, IPI‐145‐02, which confirmed that dose for further clinical development. Overall response rate was 71.8%. Median progression‐free survival was 13.7 months. Median overall survival has not been reached, but 30‐month overall survival probability was 62%. Duvelisib combined with rituximab, or bendamustine and rituximab did not appear to increase toxicities beyond the known safety profile of the individual agents. Further study is needed to determine if these combinations improve efficacy.Keywords
This publication has 25 references indexed in Scilit:
- DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin LymphomaJournal of Clinical Oncology, 2019
- The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLLBlood, 2018
- Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemiaExpert Opinion on Investigational Drugs, 2017
- PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironmentBlood Cancer Journal, 2017
- Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protectionOncotarget, 2016
- The PI3K pathway: clinical inhibition in chronic lymphocytic leukemiaSeminars in Oncology, 2016
- The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLLLeukemia, 2015
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemiaBlood, 2014
- Targeting the phosphoinositide 3-kinase pathway in hematologic malignanciesHaematologica, 2014
- PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphomaBlood, 2012